New combo therapy shows promise for tough kidney cancer
NCT ID NCT05468697
First seen Jan 25, 2026 · Last updated May 22, 2026 · Updated 20 times
Summary
This study tests a new drug combination (belzutifan plus palbociclib) against belzutifan alone in 60 adults with advanced clear-cell kidney cancer that worsened after at least two prior treatments. The goal is to see if the combination is safe and effective, and to find the best dose of palbociclib. Participants must have stage IV cancer with a clear-cell component and have tried prior immunotherapy and targeted therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Medical Center-Cancer Clinical Trials Office ( Site 1001)
Boston, Massachusetts, 02215, United States
-
Emek Medical Center-oncology ( Site 3003)
Afula, 1834111, Israel
-
Frankston Hospital-Oncology and Haematology ( Site 2005)
Frankston, Victoria, 3199, Australia
-
Georgetown University Medical Center ( Site 1002)
Washington D.C., District of Columbia, 20007, United States
-
Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 1004)
Salt Lake City, Utah, 84112, United States
-
Macquarie University-MQ Health Clinical Trials Unit ( Site 2001)
Macquarie University, New South Wales, 2109, Australia
-
One Clinical Research ( Site 2008)
Nedlands, Western Australia, 6009, Australia
-
Rabin Medical Center-Oncology ( Site 3004)
Petah Tikva, 4941492, Israel
-
Rambam Health Care Campus-Oncology ( Site 3000)
Haifa, 3109601, Israel
-
Shaare Zedek Medical Center-Oncology ( Site 3002)
Jerusalem, 9103102, Israel
-
Sourasky Medical Center ( Site 3005)
Tel Aviv, 6423906, Israel
-
University of Chicago Medical Center ( Site 1007)
Chicago, Illinois, 60637, United States
-
Westmead Hospital ( Site 2006)
Westmead, New South Wales, 2145, Australia
Conditions
Explore the condition pages connected to this study.